News & Events

Real-World Drug Development at the Targeted Therapies of Lung Cancer Meeting

Real-World Drug Development at the Targeted Therapies of Lung Cancer Meeting

The development of new treatments for any disease relies on the collaborative efforts of many different stakeholders, such as scientists, clinicians, patient advocacy groups, regulators, and pharmaceutical and biotech companies. During scientific conferences that happen throughout the year, stakeholders cobble together opportunities to discuss the current state of treatments and strategize ways to bring emerging lifesaving treatments to patients. Each year, there is one key conference…

All About Biomarker Testing & KRAS+ Lung Cancer

All About Biomarker Testing & KRAS+ Lung Cancer

Patient Rosemary Conway was joined by LUNGevity's Dr. Amy Moore and Hatim Husain, an oncologist at UCSD, to discuss biomarker testing and progress in KRAS-positive lung cancer.

Improving Treatment for KRAS-Mutant Lung Cancer

Improving Treatment for KRAS-Mutant Lung Cancer

While targeted therapies have emerged in the past decade to improve treatment of non-small cell lung cancer (NSCLC) with some types of driver mutations (such as EGFR and ALK), lung adenocarcinomas with KRAS driver mutations have been notoriously difficult to study and treat. KRAS is just one member of a large family of proteins, called RTKs (receptor tyrosine kinases), that span from the surface of the cell into the cell’s interior. This positioning allows RTKs to detect signals (such as…

Key Findings from ASCO 2022

Key Findings from ASCO 2022

Upal Basu Roy, PhD, MPH, LUNGevity's Executive Director of Research, speaks with Charles Rudin, MD, PhD, about the key findings from the recent meeting of the American Society for Clinical Oncology (ASCO) and what they mean for the lung cancer community.

We're Live-Tweeting from ASCO June 3-7!

We're Live-Tweeting from ASCO June 3-7!

LUNGevity’s Dr. Upal Basu Roy and Dr. Amy Moore will be live-tweeting from the American Society of Clinical Oncology (ASCO) annual meeting. Follow LUNGevity on Twitter and the hashtags #ASCO22 and #LCSM to be a part of the action. Times and topics of live-tweeted sessions are as follows: Fri, Jun 3, 2022 | 2:00 PM – 5:00 PM EDT | Lung Cancer—Non-Small Cell Metastatic  Sun, Jun 5, 2022 | 9:00 AM – 10:15 AM EDT | Treatment Sequencing in Resectable Lung Cancer…

Lung Cancer Treatment Landscape: New Options and Ongoing Challenges

Lung Cancer Treatment Landscape: New Options and Ongoing Challenges

Drs. Upal Basu Roy, Amy Moore, and Dhru Deb discuss their recent publication in which they presented an analysis of the lung cancer drug pipeline. They talk about what it means for patients, new drugs under development for NSCLC and SCLC, and some of the ongoing challenges and opportunities this rapid growth means for the lung cancer community.

New Options in Adjuvant Therapy for Early-Stage NSCLC

New Options in Adjuvant Therapy for Early-Stage NSCLC

Historically, surgery has been the most effective treatment for patients with early-stage non-small cell lung cancer (NSCLC). While technological improvements, such as the development of minimally invasive techniques (such as video-assisted thoracoscopic surgery or VATS), have made surgeries safer for patients, the ability to cure early-stage NSCLC patients hasn’t improved significantly in recent decades. Even after successful surgeries that completely remove the visible tumor, about half of…

Highlights of the 2022 AACR meeting

Highlights of the 2022 AACR meeting

The American Association for Cancer Research (AACR) 2022 meeting was held in New Orleans from April 9 to 13. Doctors and researchers worldwide joined together virtually and in person to make this year’s meeting one of the largest gatherings since the start of the pandemic. They shared the many exciting developments in cancer research and treatment that emerged over the last year. This year’s meeting is another testament to “Science doesn’t stop, and scientists never sleep!” Here, we discuss…

KRAS: How It Started vs. How It’s Going

KRAS: How It Started vs. How It’s Going

On May 28, 2021, the United States Food & Drug Administration (FDA) approved sotorasib as the first targeted therapy for patients with KRAS G12C-positive non-small cell lung cancer (NSCLC). Both researchers and patients celebrated this historic breakthrough, which had been a goal since the KRAS oncogene was discovered 40 years ago. KRAS is a leading driver mutation in various forms of cancer. Still, targeting KRAS had failed for nearly four decades, leading many to believe that it was “…

All Things KRAS: A Conversation with Terri Conneran and Dr. Darryl McConnell

All Things KRAS: A Conversation with Terri Conneran and Dr. Darryl McConnell

On January 31, 2022,  Amy Moore, PhD, brought us an update on KRAS. Dr. Moore, LUNGevity's Vice President of Global Engagement and Patient Partnerships, spoke with Terri Conneran, KRAS lung cancer survivor and founder of the KRAS Kickers; and Darryl McConnell, PhD, Research Site Head at Boehringer Ingelheim in Vienna, Austria.